{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T17:11:42Z","timestamp":1784308302873,"version":"3.55.0"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2019,5,8]],"date-time":"2019-05-08T00:00:00Z","timestamp":1557273600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Herpes zoster (HZ) develops in up to 50% of unvaccinated individuals, accounting for &amp;gt;1 million cases annually in the United States. A live attenuated HZ vaccine (LAV) is Food and Drug Administration approved for those age 50 years or older, though Advisory Committee on Immunization Practices recommendations are only for those age 60 years or older. LAV efficacy is ~70% for persons 50\u201359 years of age, with lower efficacy in older adults. A new 2-dose adjuvanted subunit vaccine (SUV) has &amp;gt;95% efficacy in persons 50\u201369 years of age and remains ~90% efficacious in persons vaccinated at age 70 years.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>To estimate the relative cost-effectiveness of SUV, LAV, and no vaccination (NoV) strategies, a Markov model was developed based on published data on vaccine efficacy, durability of protection, quality of life, resource utilization, costs, and disease epidemiology. The perspective was US societal, and the cycle length was 1 year with a lifelong time horizon. SUV efficacy was estimated to wane at the same rate as LAV. Outcomes evaluated included lifetime costs, discounted life expectancy, and incremental cost-effectiveness ratios (ICERs).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>For individuals vaccinated at age 50 years, the ICER for LAV vs NoV was $118 535 per quality-adjusted life-year (QALY); at age 60 years, the ICER dropped to $42 712\/QALY. SUV was more expensive but had better ICERs than LAV. At age 50, the ICER was $91 156\/QALY, and it dropped to $19 300\/QALY at age 60.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Vaccination with SUV was more cost-effective than LAV in all age groups studied. Vaccination with SUV at age 50 years appears cost-effective, with an ICER &amp;lt;$100 000\/QALY.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofz219","type":"journal-article","created":{"date-parts":[[2019,5,8]],"date-time":"2019-05-08T16:49:37Z","timestamp":1557334177000},"source":"Crossref","is-referenced-by-count":13,"title":["A Cost-effectiveness Analysis of an Adjuvanted Subunit Vaccine for the Prevention of Herpes Zoster and Post-herpetic Neuralgia"],"prefix":"10.1093","volume":"6","author":[{"given":"Christopher F","family":"Carpenter","sequence":"first","affiliation":[{"name":"Section of Infectious Diseases, Department of Internal Medicine, Beaumont Health, Royal Oak, Michigan"},{"name":"Oakland University William Beaumont School of Medicine, Rochester, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annas","family":"Aljassem","sequence":"additional","affiliation":[{"name":"Oakland University William Beaumont School of Medicine, Rochester, Michigan"},{"name":"Department of Physical Medicine and Rehabilitation, Beaumont Health, Royal Oak, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry","family":"Stassinopoulos","sequence":"additional","affiliation":[{"name":"Department of Surgery, Henry Ford Hospital, Detroit, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Pisacreta","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, Beaumont Health, Royal Oak, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Hutton","sequence":"additional","affiliation":[{"name":"School of Public Health, University of Michigan, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,5,8]]},"reference":[{"key":"2020081003570791100_CIT0001","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1056\/NEJMcp1302674","article-title":"Clinical practice: herpes zoster","volume":"369","author":"Cohen","year":"2013","journal-title":"N Engl J Med"},{"key":"2020081003570791100_CIT0002","first-page":"1","article-title":"Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"57","author":"Harpaz","year":"2008","journal-title":"MMWR Recomm Rep"},{"key":"2020081003570791100_CIT0003","doi-asserted-by":"crossref","first-page":"781","DOI":"10.2165\/11317560-000000000-00000","article-title":"Incremental 1-year medical resource utilization and costs for patients with herpes zoster from a set of US health plans","volume":"27","author":"White","year":"2009","journal-title":"Pharmacoeconomics"},{"key":"2020081003570791100_CIT0004","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1093\/cid\/cir970","article-title":"Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years","volume":"54","author":"Schmader","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2020081003570791100_CIT0005","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa051016","article-title":"A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"352","author":"Oxman","year":"2005","journal-title":"N Engl J Med"},{"key":"2020081003570791100_CIT0006","first-page":"1320","article-title":"Long-term persistence of zoster vaccine efficacy","volume":"55","author":"Morrison","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2020081003570791100_CIT0007","first-page":"729","article-title":"Update on recommendations for use of herpes zoster vaccine","volume":"63","author":"Hales","year":"2014","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2020081003570791100_CIT0008","doi-asserted-by":"crossref","first-page":"103","DOI":"10.15585\/mmwr.mm6703a5","article-title":"Recommendations of the advisory committee on immunization practices for use of herpes zoster vaccines","volume":"67","author":"Dooling","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2020081003570791100_CIT0009","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"N Engl J Med"},{"key":"2020081003570791100_CIT0010","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","article-title":"Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older","volume":"375","author":"Cunningham","year":"2016","journal-title":"N Engl J Med"},{"key":"2020081003570791100_CIT0011","doi-asserted-by":"crossref","first-page":"8326","DOI":"10.1016\/j.vaccine.2007.09.066","article-title":"Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"25","author":"Pellissier","year":"2007","journal-title":"Vaccine"},{"key":"2020081003570791100_CIT0012","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1086\/514342","article-title":"Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"44","author":"Rothberg","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2020081003570791100_CIT0013","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1086\/523011","article-title":"Cost-effectiveness of herpes zoster vaccine: flawed assumptions regarding efficacy against postherpetic neuralgia","volume":"45","author":"Brisson","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2020081003570791100_CIT0014","doi-asserted-by":"crossref","first-page":"489","DOI":"10.7326\/M15-0093","article-title":"Cost-effectiveness of herpes zoster vaccine for persons aged 50 years","volume":"163","author":"Le","year":"2015","journal-title":"Ann Intern Med"},{"key":"2020081003570791100_CIT0015","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s40273-012-0020-7","article-title":"A systematic review of the cost effectiveness of herpes zoster vaccination","volume":"31","author":"Szucs","year":"2013","journal-title":"Pharmacoeconomics"},{"key":"2020081003570791100_CIT0016","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1016\/j.vaccine.2014.01.058","article-title":"Cost-effectiveness of vaccination against herpes zoster and postherpetic neuralgia: a critical review","volume":"32","author":"Kawai","year":"2014","journal-title":"Vaccine"},{"key":"2020081003570791100_CIT0017","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.4161\/hv.28670","article-title":"Cost-effectiveness of vaccination against herpes zoster","volume":"10","author":"de Boer","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"2020081003570791100_CIT0018","doi-asserted-by":"crossref","first-page":"317","DOI":"10.7326\/0003-4819-145-5-200609050-00004","article-title":"Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"145","author":"Hornberger","year":"2006","journal-title":"Ann Intern Med"},{"key":"2020081003570791100_CIT0019","volume-title":"Economic evaluation of vaccination for prevention of herpes zoster and related complications","author":"Prosser"},{"key":"2020081003570791100_CIT0020","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1001\/jamainternmed.2017.7431","article-title":"Cost-effectiveness of the adjuvanted herpes zoster subunit vaccine in older adults","volume":"178","author":"Le","year":"2018","journal-title":"JAMA Intern Med"},{"key":"2020081003570791100_CIT0021","doi-asserted-by":"crossref","first-page":"5037","DOI":"10.1016\/j.vaccine.2018.07.005","article-title":"Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States","volume":"36","author":"Curran","year":"2018","journal-title":"Vaccine"},{"key":"2020081003570791100_CIT0022","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1186\/s12879-015-1262-8","article-title":"Annual incidence rates of herpes zoster among an immunocompetent population in the United States","volume":"15","author":"Johnson","year":"2015","journal-title":"BMC Infect Dis"},{"key":"2020081003570791100_CIT0023","article-title":"National vital statistics reports","volume-title":"United States life tables, 2011","author":"National Center for Health Statistics, Centers for Disease Control and Prevention, US Department of Health and Human Services","year":"2015"},{"key":"2020081003570791100_CIT0024","volume-title":"Making Good Decisions: Examining the Cost-effectiveness and Optimal Timing of the Herpes Zoster Vaccine [doctoral dissertation]","author":"Harvey","year":"2016"},{"key":"2020081003570791100_CIT0025","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/j.vaccine.2012.01.045","article-title":"Employment related productivity loss associated with herpes zoster and postherpetic neuralgia: a 6-month prospective study","volume":"30","author":"Drolet","year":"2012","journal-title":"Vaccine"},{"key":"2020081003570791100_CIT0026","volume-title":"US Bureau of Economic Analysis. Gross Domestic Product: Implicit Price Deflator (GDPDEF), retrieved from FRED, Federal Reserve Bank of St. Louis"},{"key":"2020081003570791100_CIT0027","volume-title":"CDC Vaccine Price List"},{"key":"2020081003570791100_CIT0028","author":"Centers for Medicare & Medicaid Services"},{"key":"2020081003570791100_CIT0029","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2165\/00019053-200826030-00006","article-title":"Community and patient values for preventing herpes zoster","volume":"26","author":"Lieu","year":"2008","journal-title":"Pharmacoeconomics"},{"key":"2020081003570791100_CIT0030","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1177\/0272989X06290497","article-title":"Report of nationally representative values for the noninstitutionalized US adult population for 7 health-related quality-of-life scores","volume":"26","author":"Hanmer","year":"2006","journal-title":"Med Decis Making"},{"key":"2020081003570791100_CIT0031","volume-title":"Compressed mortality file 1999\u20132015 on CDC WONDER online database, released December 2016","author":"Centers for Disease Control and Prevention, National Center for Health Statistics"},{"key":"2020081003570791100_CIT0032","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1016\/j.amjmed.2013.09.013","article-title":"Anaphylaxis: a payor\u2019s perspective on epinephrine autoinjectors","volume":"127","author":"Dunn","year":"2014","journal-title":"Am J Med"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofz219\/28571832\/ofz219.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/6\/7\/ofz219\/33589792\/ofz219.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/6\/7\/ofz219\/33589792\/ofz219.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T08:06:54Z","timestamp":1597046814000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofz219\/5487167"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,8]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofz219","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,7]]},"published":{"date-parts":[[2019,5,8]]},"article-number":"ofz219"}}